Skip to main content Skip to search Skip to main navigation

Swissmedic: Update of Responsible Person Requirements

Swissmedic published an updated version of Technical Interpretation 17: Responsible Person: requirements on 26 August 2024. The document outlines the Swiss Inspectorate’s understanding of an RP in accordance with the Medicinal Products Licensing Ordinance (MPLO). It can also serve as a reference for companies to assess whether an individual meets the criteria for applying to Swissmedic to act as an RP.

What’s new in Version 7.0?

  • Chapters 5.1 and 5.2 provide precise information about educational aspects and activities where experience in GDP/GMP practices is required.
  • The experience with regulatory issues as acceptable criterium has been removed and a precision about the experience required for an area with specific risks was added (e.g. sterile medicinal products)
  • It is specified that brokerage, agents, and trade in foreign countries do not count as GDP experience.
  • Language requirements are clarified in Chapter 5.5
  • Chapter 5.6. specifies the understanding of what is the direct supervision of a facility.
  • New Chapter 5.6.1 on remote technical and market release
  • Chapter 5.2 includes:
  • - Precisions about the expected presence on site of the RPs,
    - Precision of conditions permitting a reduction of physical presence on site,
    - Precision on the cases where an intensified presence on site is expected.
  • New Chapter on 5.6.3 about the workload of RPs
  • Chapter 6 clarifies that the same requirements apply to the deputy RP, inclusive domicile.
  • Chapter 7 specifies possibilities and conditions for task delegation as well as critical processes and release activities.
  • Chapter 8 includes the event of absence of the RP beyond the normal holiday leave.

In most cases, compliance with the previous technical interpretation guarantees compliance with the current version. The license holder is generally required to adapt immediately. Also, for the inspectorates the updated technical interpretation applies with immediate effect.

License holders with approved responsible persons who do not meet the requirements have 12 months to make the necessary adjustments. This could be either by appointing a new RP with the required language skills or by ensuring that an RP acquires the required language skills within this period. Swissmedic expects responsible persons to speak one of the official local languages of the canton where the inspection takes place and where the site is located.


Source:

Swissmedic: Technical interpretation 17 “Responsible Person: requirements”

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

ICH: Updated Q9(R1) Briefing Pack

ICH: Updated Q9(R1) Briefing Pack

The ICH has fully revised the Q9(R1) Briefing Pack (March/April 2026) to align with the updated ICH Q9 guideline.
Read more
EMA: New Plans for the EU GMP Guide

EMA: New Plans for the EU GMP Guide

EMA published the GMDP Inspectors Working Group’s new 2026-2028 work plan and its 2025 annual report.
Read more
EMA: Pharmaceutical Quality System (PQS) Effectiveness Pilot Project

EMA: Pharmaceutical Quality System (PQS) Effectiveness Pilot Project

EMA launched a pilot under which EEA GMP inspectors will assess how sites demonstrate the effectiveness of their pharmaceutical quality system for risk-based change management, and whether the EEA GMP certificate could serve as the main evidence of this effectiveness.
Read more
EMA: Updated Guideline on Active Substance Chemistry

EMA: Updated Guideline on Active Substance Chemistry

The EMA has updated guidance on the information required for the manufacture and control of active substances used in medicinal products, with a 1 September 2026 date of application.
Read more
EMA: Q&A on the Implementation of 3DP Technology for Solid Oral Dosage Forms

EMA: Q&A on the Implementation of 3DP Technology for Solid Oral Dosage Forms

EMA added a new GMP/Q&A section on its website and published a dedicated Q&A document on 3D printing (3DP) for solid oral dosage forms.
Read more
Microbiological Monitoring – Sources of Contamination

Microbiological Monitoring – Sources of Contamination

All pharmaceutical dosage forms must be manufactured under controlled microbiological conditions. This requires microbial monitoring. This applies not only to sterile manufacturing, but also to facilities that manufacture non-sterile products.
Read more
Previous
Next